Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 10 of 12 descriptions
| No. | 薬物名（臨床試験情報から抽出） | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | 指定難病告示番号 | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Dexdor | 1件: Dexmedetomidine Dexmedetomidine (Dexdor) | 1件: Dexmedetomidine
Dexmedetomidine
(Dexdor (TN)) 💬1. Dexdor
| 3件: ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 4件: 2 2, 4, 6, 70 💬
| |||||||||||||||||||||||||||||||||||||||||||||||||
| 2 | Dexmedetomidine (Dexdor (TN)) | 1件: Dexmedetomidine Dexmedetomidine (Dexdor) | 1件: Dexmedetomidine
Dexmedetomidine
(Dexdor (TN)) 💬2. Dexmedetomidine
| 3件: ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 14件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬2. Dexmedetomidine
| |||||||||||||||||||||||||||||||||||||||||||||||||
| 3 | Dexmedetomidine 1 (Dexdor (TN)) | 1件: Dexmedetomidine Dexmedetomidine (Dexdor) | 1件: Dexmedetomidine
Dexmedetomidine
(Dexdor (TN)) 💬3. Dexmedetomidine 1
| 3件: ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 280 280 💬3. Dexmedetomidine 1
| |||||||||||||||||||||||||||||||||||||||||||||||||
| 4 | Dexmedetomidine 2 (Dexdor (TN)) | 1件: Dexmedetomidine Dexmedetomidine (Dexdor) | 1件: Dexmedetomidine
Dexmedetomidine
(Dexdor (TN)) 💬4. Dexmedetomidine 2
| 3件: ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 280 280 💬4. Dexmedetomidine 2
| |||||||||||||||||||||||||||||||||||||||||||||||||
| 5 | Dexmedetomidine 3 (Dexdor (TN)) | 1件: Dexmedetomidine Dexmedetomidine (Dexdor) | 1件: Dexmedetomidine
Dexmedetomidine
(Dexdor (TN)) 💬5. Dexmedetomidine 3
| 3件: ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 280 280 💬5. Dexmedetomidine 3
| |||||||||||||||||||||||||||||||||||||||||||||||||
| 6 | Dexmedetomidine group (Dexdor (TN)) | 1件: Dexmedetomidine Dexmedetomidine (Dexdor) | 1件: Dexmedetomidine
Dexmedetomidine
(Dexdor (TN)) 💬6. Dexmedetomidine group
| 3件: ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 70 70 💬6. Dexmedetomidine group
| |||||||||||||||||||||||||||||||||||||||||||||||||
| 7 | Dexmedetomidine Hcl 100 Mcg/mL Inj (Dexdor (TN)) | 1件: Dexmedetomidine Dexmedetomidine (Dexdor) | 1件: Dexmedetomidine
Dexmedetomidine
(Dexdor (TN)) 💬7. Dexmedetomidine Hcl 100 Mcg/mL Inj
| 3件: ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 215 215 💬7. Dexmedetomidine Hcl 100 Mcg/mL Inj
| |||||||||||||||||||||||||||||||||||||||||||||||||
| 8 | DEXMEDETOMIDINE HYDROCHLORIDE (Dexdor (TN)) | 1件: Dexmedetomidine Dexmedetomidine (Dexdor) | 1件: Dexmedetomidine
Dexmedetomidine
(Dexdor (TN)) 💬8. DEXMEDETOMIDINE HYDROCHLORIDE
| 3件: ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 70 70 💬8. DEXMEDETOMIDINE HYDROCHLORIDE
| |||||||||||||||||||||||||||||||||||||||||||||||||
| 9 | Dexmedetomidine Hydrochloride Infusion (Dexdor (TN)) | 1件: Dexmedetomidine Dexmedetomidine (Dexdor) | 1件: Dexmedetomidine
Dexmedetomidine
(Dexdor (TN)) 💬9. Dexmedetomidine Hydrochloride Infusion
| 3件: ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬9. Dexmedetomidine Hydrochloride Infusion
| |||||||||||||||||||||||||||||||||||||||||||||||||
| 10 | Dexmedetomidine with ropivacaine (Dexdor (TN)) | 2件: Dexmedetomidine Dexmedetomidine (Dexdor),Ropivacaine | 2件: Dexmedetomidine
Dexmedetomidine
(Dexdor (TN)),Ropivacaine 💬 10. Dexmedetomidine with ropivacaine
| 8件: ADRA2A ADRA2A,ADRA2B, ADRA2C, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 10. Dexmedetomidine with ropivacaine
| 5件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Neuroactive ligand-receptor interaction, Taste transduction, cGMP-PKG signaling pathway 💬 5件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Neuroactive ligand-receptor intera ... | 1件: 70 70 💬10. Dexmedetomidine with ropivacaine
|